Holland & Knight Health Dose: May 21, 2024

HK
Holland & Knight

Contributor

Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
United States Food, Drugs, Healthcare, Life Sciences

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.

This week's topics include:

  • FY 2025 Spending Bills Begin to Take Shape; Budget Hearings Continue
  • FAA Reauthorization
  • House BIOSECURE Bill Advances Out of Committee
  • Bipartisan Senate Group Releases Draft Electronic Prior Authorization Legislation
  • Senate White Paper, Discussion Draft and RFI on Proposed Medicare Payment Reforms
  • Bipartisan Senate Workgroup Releases AI Roadmap
  • House E&C Subcommittee on Health Marks Up 23 Bills, Including Telehealth Extender Bill
  • Senate HELP Committee to Hold Public Health Reauthorization Markup
  • Senate Judiciary Committee to Examine Prescription Drug Costs
  • House Hearings on Healthcare Consolidation
  • House E&C Committee to Hold Hearing Featuring CBER, CDER, CDRH Directors
  • Senate HELP Subcommittee Hearing on "Food in Medicine"
  • Upcoming Senate Finance Committee Hearing on Fentanyl
  • ARPA-H "Upgrade" Investment in Cybersecurity
  • FDA ICER Framework for Clinical Trial Diversity
  • CBER Statement on IRA Drug Negotiation Program

Read the full Health Dose »

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More